The history of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated significant returns, the end of its patent opened the avenue to off-brand competitors, https://businessbookmark.com/story7229954/the-copyright-and-the-pharmaceutical-industry-a-volatile-opportunity